- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03183661
A Follow-up Study to Evaluate the Safety of ALLO-ASC-CD in ALLO-ASC-CD-101 Clinical Trial
Follow-up Study to Evaluate the Safety of ALLO-ASC-CD in the Subjects With Crohn´s Disease(ALLO-ASC-CD-101)
Study Overview
Detailed Description
This is an open-label follow up study to evaluate the safety for the subjects with ALLO-ASC-CD injection in phase 1 clinical trial (ALLO-ASC-CD-101) for 36 months.
ALLO-ASC-CD is intravenous infusion containing allogenic adipose-derived mesenchymal stem cells. Adipose-derived stem cells are directed to injured tissue, and reduce inflammation. Furthermore their immunomodulatory effects are significant for treating immune-related disease, such as crohn's disease. Finally, ALLO-ASC-CD may provide a new option in treating a crohn's disease.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Jae Hee Cheon, Ph D
- Email: GENIUSHEE@yuhs.ac
Study Locations
-
-
-
Seoul, Korea, Republic of, 03080
- Recruiting
- Seoul National University Hospital
-
Contact:
- Joosung Kim, MD, Ph.D.
- Email: jooskim@snu.ac.kr,
-
Seoul, Korea, Republic of, 03722
- Completed
- Severance Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Subjects who are injected with ALLO-ASC-CD in phase 1 clinical trial of ALLO-ASC-CD-101.
- Subjects who are able to give written informed consent prior to study start and to comply with the study requirements.
Exclusion Criteria:
1. Subjects who are considered not suitable for the study by the principal investigator.
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
ALLO-ASC-CD injection
Subjects with ALLO-ASC-CD injection in phase 1 clinical trial of ALLOASC-CD-101
|
ALLO-ASC-CD is intravenous infusion containing allogenic adipose-derived mesenchymal stem cells.
Adipose-derived stem cells are directed to injured tissue, and reduce inflammation.
Furthermore their immunomodulatory effects are significant for treating immune-related disease.
Finally, ALLO-ASC-CD may provide a new option in treating a crohn's disease.
This study is a follow-up study without intervention.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants with Adverse Events as a Measure of Safety and Tolerability
Time Frame: up to 36 months
|
Evaluation of AE
|
up to 36 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Joo Sung Kim, Ph D, Seoul National University Hospital
- Principal Investigator: Young Ho Kim, Ph D, Samsung Medical Center
- Principal Investigator: Jae Hee Cheon, Ph D, Yonsei University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ALLO-ASC-CD-102
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Crohn Disease
-
ProgenaBiomeRecruitingCrohn Disease | Crohn Colitis | Crohn's Ileocolitis | Crohn's Gastritis | Crohn's Jejunitis | Crohn's Duodenitis | Crohn's Esophagitis | Crohn's | Crohn Disease of Ileum | Crohn Ileitis | Crohn's Disease Relapse | Crohns Disease Aggravated | Crohn Disease in Remission | Crohn's Disease of PylorusUnited States
-
Academisch Medisch Centrum - Universiteit van Amsterdam...CelltrionRecruitingBowel Disease | Inflammatory Disease | Disease CrohnNetherlands
-
Chinese University of Hong KongTerminatedCrohn Disease | Perianal Crohn DiseaseHong Kong
-
SandozCompletedCrohn´s DiseaseAustria, Germany, Poland, Spain, Sweden
-
Dr. Falk Pharma GmbHCompleted
-
University of Erlangen-Nürnberg Medical SchoolCompleted
-
Groupe Hospitalier Paris Saint JosephCompleted
-
Ferring PharmaceuticalsTerminatedCrohn´s DiseaseUnited Kingdom, United States, Germany, Belgium, Denmark, France, Sweden
-
Jinling Hospital, ChinaCompletedCrohn Disease in RemissionChina
-
Boehringer IngelheimTerminatedFibrostenotic Crohn´s DiseaseUnited States, Canada, Japan, Sweden
Clinical Trials on ALLO-ASC-CD
-
Anterogen Co., Ltd.RecruitingCrohn's DiseaseKorea, Republic of
-
Anterogen Co., Ltd.Completed
-
Anterogen Co., Ltd.CompletedDiabetic Foot UlcerKorea, Republic of
-
Anterogen Co., Ltd.RecruitingDiabetic Foot UlcerKorea, Republic of
-
Anterogen Co., Ltd.RecruitingDystrophic Epidermolysis BullosaUnited States
-
Anterogen Co., Ltd.RecruitingDiabetic Foot UlcerKorea, Republic of
-
Anterogen Co., Ltd.CompletedDiabetic Foot UlcerKorea, Republic of
-
Anterogen Co., Ltd.CompletedCrohnKorea, Republic of
-
Yonsei UniversityCompleted
-
Anterogen Co., Ltd.CompletedDystrophic Epidermolysis BullosaKorea, Republic of